A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

Stopped The study was closed due to investigator discretion based on the lack of ability to recruit patients and research goals of the program.

Conditions

• Papillomavirus Infections
• Oropharyngeal Neoplasms

Interventions

• BIOLOGICAL: E7 TCR

Sponsor

National Cancer Institute (NCI)